Comparative Pharmacology
Head-to-head clinical analysis: NEVIRAPINE versus PIFELTRO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEVIRAPINE versus PIFELTRO.
NEVIRAPINE vs PIFELTRO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds directly to HIV-1 reverse transcriptase, causing a conformational change that inhibits enzyme activity and viral replication.
Selective allosteric inhibitor of HIV-1 capsid protein, interfering with multiple steps of the viral life cycle including capsid assembly, nuclear import, and virion maturation.
200 mg orally once daily for 14 days, then 200 mg orally twice daily (immediate-release); 400 mg orally once daily (extended-release). Administered in combination with other antiretroviral agents.
200 mg orally once daily, taken with or without food.
None Documented
None Documented
Clinical Note
moderateNevirapine + Digoxin
"The metabolism of Digoxin can be increased when combined with Nevirapine."
Clinical Note
moderateNevirapine + Digitoxin
"The metabolism of Digitoxin can be increased when combined with Nevirapine."
Clinical Note
moderateNevirapine + Clobetasol propionate
"The serum concentration of Clobetasol propionate can be decreased when it is combined with Nevirapine."
Clinical Note
moderateNevirapine + Estrone sulfate
Terminal elimination half-life: 25-30 hours after single dose; decreases to 20-25 hours with multiple dosing due to autoinduction of CYP3A4 and CYP2B6.
12-13 hours in healthy subjects; clinically, supports once-daily dosing.
Renal: <5% unchanged; hepatic metabolism to inactive glucuronide metabolites, primarily excreted in urine (80%) and feces (10%).
Primarily hepatic metabolism with subsequent biliary/fecal elimination. 86% of a single oral dose recovered in feces (mostly as metabolites) and <1% unchanged in urine.
Category A/B
Category C
NNRTI
NNRTI
"The serum concentration of Estrone sulfate can be decreased when it is combined with Nevirapine."